Pathogenetic mechanisms of amyloid A amyloidosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 40, 2013, Pages 16115-16120

  Simons, J Paul ^a   Al Shawi, Raya ^a   Ellmerich, Stephan ^a   Speck, Ivana ^a   Aslam, Samrina ^a   Hutchinson, Winston L ^a   Mangione, Palma P ^a,b   Disterer, Petra ^a   Gilbertson, Janet A ^a   Hunt, Toby ^a   Millar, David J ^a   Minogue, Shane ^a   Bodin, Karl ^a,c   Pepys, Mark B ^a   Hawkins, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

3Rs; Disease model

Indexed keywords

AMYLOID A PROTEIN; DOXYCYCLINE; SERUM AMYLOID A;

AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOLOGY; KIDNEY FAILURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RENAL SYSTEM PARAMETERS; TISSUE STRUCTURE; TRANSGENIC MOUSE;

3RS; DISEASE MODEL;

AMYLOID; AMYLOIDOSIS; ANIMALS; CONGO RED; DNA PRIMERS; DOXYCYCLINE; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; SERUM AMYLOID A PROTEIN;

EID: 84885068904     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306621110     Document Type: Article

References (39)

1. Pepys MB (2006) Amyloidosis. Annu Rev Med 57:223-241.
2. Hoffman JS, Ericsson LH, Eriksen N, Walsh KA, Benditt EP (1984) Murine tissue amyloid protein AA. NH2-terminal sequence identity with only one of two serum amyloid protein (ApoSAA) gene products. J Exp Med 159(2):641-646.
3. Benditt EP, Eriksen N, Hanson RH (1979) Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 76(8):4092-4096.
4. Lachmann HJ, et al. (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361-2371.
5. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358(9275):24-29.
6. Jaffé RH (2001) Amyloidosis produced by injections of proteins. 1926. Arch Pathol Lab Med 125(1):25-37.
7. Janigan DT (1965) Experimental amyloidosis: Studies with a modified casein method, casein hydrolysate and gelatin. Am J Pathol 47(1):159-171.
8. Yu J, Guo JT, Zhu H, Kindy MS (2000) Amyloid formation in the rat: Adenoviral expression of mouse serum amyloid A proteins. Amyloid 7(1):32-40.
9. Yu J, Zhu H, Guo JT, de Beer FC, Kindy MS (2000) Expression of mouse apolipoprotein SAA1.1 in CE/J mice: Isoform-specific effects on amyloidogenesis. Lab Invest 80(12): 1797-1806.
10. Kistner A, et al. (1996) Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93(20):10933-10938.
11. Schönig K, Schwenk F, Rajewsky K, Bujard H (2002) Stringent doxycycline dependent control of CRE recombinase in vivo. Nucleic Acids Res 30(23):e134.
12. Parks JS, Rudel LL (1985) Alteration of high density lipoprotein subfraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. J Lipid Res 26(1):82-91.
13. PepysMB, BaltzM,Gomer K, Davies AJS, DoenhoffM(1979) Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278(5701):259-261.
14. Hawkins PN, Myers MJ, Epenetos AA, Caspi D, Pepys MB (1988) Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med 167(3):903-913.
15. Botto M, et al. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3(8):855-859.
16. Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323(8):508-513.
17. Hawkins PN, Wootton R, Pepys MB (1990) Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 86(6):1862-1869.
18. Hawkins PN (2002) Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 11(6):649-655.
19. Hawkins PN, Pepys MB (1990) A primed state exists in vivo following histological regression of amyloidosis. Clin Exp Immunol 81(2):325-328.
20. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M (1982) Further characterization of amyloid-enhancing factor. Lab Invest 47(2):139-146.
21. Baltz ML, Caspi D, Hind CRK, Feinstein A, Pepys MB (1986) Isolation and characterization of amyloid enhancing factor (AEF). Amyloidosis, eds Glenner GG, et al. (Plenum Press, New York), pp 115-121.
22. Hoffman JS, Benditt EP (1983) Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J Clin Invest 71(4):926-934.
23. Puchtler H, Sweat F, Levine M (1962) On the binding of Congo red by amyloid. J Histochem Cytochem 10(3):355-364.
24. Song S, et al. (2009) Serum cystatin C in mouse models: A reliable and precise marker for renal function and superior to serum creatinine. Nephrol Dial Transplant 24(4): 1157-1161.
25. Bodin K, et al. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320):93-97.
26. Solomon A, et al. (1999) Transgenic mouse model of AA amyloidosis. Am J Pathol 154(4):1267-1272.
27. Lachmann HJ, et al. (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746-750.
28. Agostini L, et al. (2004) NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20(3):319-325.
29. Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB (2002) Unicentric Castleman's disease complicated by systemic AA amyloidosis: A curable disease. QJM 95(4):211-218.
30. Rivas AL, Tintle L, Kimball ES, Scarlett J, Quimby FW (1992) A canine febrile disorder associated with elevated interleukin-6. Clin Immunol Immunopathol 64(1):36-45.
31. Björkman L, et al. (2010) The proinflammatory activity of recombinant serum amyloid A is not shared by the endogenous protein in the circulation. Arthritis Rheum 62(6): 1660-1665.
32. Meek RL, Hoffman JS, Benditt EP (1986) Amyloidogenesis. One serum amyloid A isotype is selectively removed from the circulation. J Exp Med 163(3):499-510.
33. Hébert L, Gervais F (1990) apo-SAA1/apo-SAA2 isotype ratios during casein-and amyloidenhancing-factor-induced secondary amyloidosis in A/J and C57BL/6J mice mice. Scand J Immunol 31(2):167-173.
34. Eriksen N, Benditt EP (1980) Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci USA 77(11): 6860-6864.
35. Liepnieks JJ, Kluve-Beckerman B, Benson MD (1995) Characterization of amyloid A protein in human secondary amyloidosis: The predominant deposition of serum amyloid A1. Biochim Biophys Acta 1270(1):81-86.
36. Cornwell GG, 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkänen P (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618-623.
37. Tanskanen M, et al. (2006) Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid 13(3):164-169.
38. Campbell-Washburn AE, et al. (2013) Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction. Amyloid 20(2):93-98.
39. Urlinger S, et al. (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97(14):7963-7968.